TAVNEOS
Peakavacopan
NDAORALCAPSULE
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
TAVNEOS (avacopan) is complement 5a receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed 3m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVNEOS (avacopan) is an oral complement 5a receptor antagonist approved in October 2021 for treating anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It works by blocking the C5a complement pathway, reducing inflammation in blood vessel-targeted autoimmune disease. This represents the first oral monotherapy option for this rare but serious condition.
$0.034BPart D
Peak13.4 years to LOEProduct is in peak lifecycle phase with modest but growing claims volume; commercial team remains lean relative to larger specialty franchises.
Mechanism of Action
Complement 5a Receptor Antagonists
Pharmacologic Class:
Complement 5a Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Started Jul 2026
30 enrolled
Granulomatosis With PolyangiitisWegener'sGPA
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Started Nov 2024
160 enrolled
ANCA Associated Vasculitis (AAV)
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Started Oct 2024
20 enrolled
Vasculitis
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
Started Jun 2024
13 enrolled
End-Stage Renal Disease (ESRD)
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Started Feb 2024
300 enrolled
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.